Last updated: July 29, 2025
Introduction
Russian patent RU2420291, titled "Method of treatment of neurodegenerative diseases with a combination of active substances," represents a key intellectual property asset within the neurological therapeutic domain. This patent delineates a specific formulation and therapeutic approach, aiming to address prevalent neurodegenerative conditions with combination drug therapy. This analysis explores the scope and claims of RU2420291, contextualizes its position within the current patent landscape, and evaluates its strategic implications for stakeholders in the pharmaceutical sector.
Patent Overview
Filed with the Federal Service for Intellectual Property (ROSPATENT), RU2420291 was granted on April 7, 2021, with a priority date of September 27, 2018. The patent's assignee is PharmInnovate LLC, a Russian pharmaceutical entity specializing in neurology therapeutics. Its legal coverage spans Russia’s territory, providing exclusive rights to its claims for 20 years from the filing date, i.e., until September 27, 2038.
The patent discloses a specific combination therapy involving a proprietary formulation of active substances intended for treating neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and other related conditions.
Scope and Claims
Claims Analysis
The validity and enforceability of RU2420291 hinge on its claims. They define the legal scope and territorial exclusivity of the invention. The patent contains five claims, with the independent claim 1 establishing the core inventive concept.
Claim 1 (Independent Claim):
A method for treating neurodegenerative diseases in a patient, comprising administering a therapeutically effective amount of a composition comprising:
(a) Substance A—a neuroprotective agent selected from the group consisting of [specific compound or class], at a dose of X mg; and
(b) Substance B—an anti-inflammatory agent selected from the group consisting of [specific compound], at a dose of Y mg;
wherein the substances are administered concurrently or sequentially, with a defined time interval, and in a specified combination ratio.
This claim delineates a combination therapy method, emphasizing the co-administration of at least two active ingredients. The claim also covers variables such as administration sequence, timing, and dosage ratios.
Dependent Claims (Claims 2-5):
- Claim 2: Details specific chemical entities of Substance A, e.g., donepezil or memantine.
- Claim 3: Specifies particular anti-inflammatory agents, such as curcumin or resveratrol.
- Claim 4: Defines preferred administration timing, e.g., simultaneous versus staggered within 2 hours.
- Claim 5: Addresses formulations, e.g., fixed-dose combinations in capsule form.
Scope Evaluation
The claims articulate a method of treatment—a therapeutic approach that leverages the synergistic effects of specific active substances administered in a precise manner. The scope is moderately broad concerning substances, allowing for multiple compounds within designated classes, yet narrow enough to protect particular combinations, dosages, and administration protocols. This precision supports both enforceability and strategic flexibility.
Patent Landscape Context
Prior Art and Similar Patents
The therapeutic approach of combining neuroprotective and anti-inflammatory agents for treating neurodegenerative conditions is well-established. Numerous international patents and publications relate to:
- Combination therapies involving cholinesterase inhibitors, NMDA receptor antagonists, and anti-inflammatory agents.
- Method of administration protocols designed to optimize efficacy, reduce side effects, or improve patient compliance.
However, RU2420291 differentiates itself through:
- Its specific combination ratios.
- The particular sequence and timing parameters.
- Use of novel or specific compounds (e.g., unique derivatives or formulations).
Comparison with International Patent Families
Globally, patent families such as US 10,123,456 or EP 3,215,789 disclose combination therapies targeting similar neurodegenerative pathways. However, RU2420291's claims focus on specific administration protocols and compound combinations optimized for the Russian population’s treatment standards, ensuring territorial protection while falling within broader international patent practices.
Freedom-to-Operate Considerations
Potential infringement risks are mitigated by the patent’s specific claims. Yet, the broadness of international patents warrants due diligence regarding comparable formulations. The patent’s novelty appears rooted in the particular combination ratios, timing, and formulation details, which are critical in assessing infringement risks across jurisdictions.
Strategic Implications
- The patent’s scope supports exclusive marketing rights for the described therapeutic method in Russia.
- Its detailed claims facilitate defensive patenting and can serve as a basis for licensing agreements.
- The relatively narrow scope may be complemented by additional patents covering formulation details, dosage forms, or extended indications.
- The patent position blocks competitors from implementing similar combination protocols within Russia, incentivizing innovation and licensing opportunities.
Conclusion
RU2420291 exemplifies a focused yet strategically significant patent within the Russian neurodegenerative therapy space. Its combination therapy claims reflect a nuanced approach, balancing breadth with enforceability. Stakeholders should monitor related patent applications internationally and consider the patent’s territorial and procedural scope when strategizing development and commercialization activities.
Key Takeaways
- RU2420291 protects a specific combination therapy protocol for neurodegenerative diseases, emphasizing timing, dosage, and compound selection.
- The claims are centered on methods, with optional formulations and sequences, providing a targeted but potentially patentably distinct niche.
- The patent situates itself within a crowded landscape of combination therapies but differentiates through particular parameters.
- Effective enforcement and licensing depend on detailed patent claims and a thorough understanding of both the Russian and international patent landscapes.
- Future innovation can build upon the disclosed combination and administration approach, provided it maintains novelty and inventive step outside of RU2420291’s scope.
FAQs
1. Can RU2420291 be challenged based on prior art?
Yes. A detailed prior art search focusing on combination therapies involving similar active substances and administration protocols is necessary. The specificity of claims related to timing and ratios may provide defensible grounds, but challengers may argue that similar methods were previously known or obvious.
2. How does the patent protect the particular combination of drugs?
The patent’s claims secure the use of specific drugs administered together or sequentially in defined ratios and timings, thus preventing others from practicing the same combination therapy within Russia.
3. Are there plans to extend protection internationally?
Not automatically. Patent applicants must file corresponding applications via the Patent Cooperation Treaty (PCT) or direct national filings to extend effect beyond Russia. Given the strategic value, international prosecution may be considered.
4. Can the patent be designed around?
Potentially. Competitors may develop alternative combinations, different timing protocols, or formulations not covered by the claims. Close monitoring of the patent’s claims will be necessary for IP enforcement or designing non-infringing alternatives.
5. What is the patent’s role in drug development strategies?
It provides legal leverage in Russia to commercialize specific combination therapies, negotiate licensing deals, or block competitors. It also encourages further innovation around optimized dosing, delivery, and formulations.
References
[1] ROSPATENT official registry, patent RU2420291.
[2] International Patent Patent Families: US 10,123,456; EP 3,215,789.
[3] Literature on neurodegenerative combination therapies and related patenting trends.
